If granted full FDA approval, which could come in early July, treatment could boost annual Medicare spending by nearly $9 billion, analysis shows.
You are here: Home / Top Stories / : FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment